CLINICAL_TRIALS
trial_result
· 2008-01-07
Clinical Trial Update: PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease [Phase 2]
Summary
This document provides an update on the PLASMA 2 Phase 2 trial evaluating once-daily dosing of A-002 in subjects with stable coronary artery disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Anthera Pharmaceuticals | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED